Detalhe da pesquisa
1.
Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+ HER2- Early Breast Cancer.
Ann Pharmacother
; : 10600280211073322, 2022 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35135362
2.
Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy.
Biomedicines
; 11(3)2023 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36979929